Avalo Therapeutics Announces Pricing of $375 Million Public Offering
Avalo Therapeutics, a clinical-stage biotech company focused on IL-1β treatments for immune-mediated inflammatory diseases, announced it has priced an underwritten public offering of approximately $375 million. The proceeds will be used to progress the Phase 3 clinical development of its lead drug candidate abdakibart and for general corporate purp…